The LEAP-007 study (NCT03829332) was a phase 3, double-blind, randomized clinical study that used pembrolizumab alone or in combination with lenvatinib in patients with advanced first-line NSCLC with programmed death ligand 1 (PD-L1) tumor proportion score (TPS) ≥ 1%; this study explored the synergistic effect of anti-angiogenic therapy with other immunotherapies. Here, CD274 is linked to neoplasm.